66
Views
41
CrossRef citations to date
0
Altmetric
Review

11β-Hydroxysteroid dehydrogenase-1 as a therapeutic target for metabolic diseases

, &
Pages 289-303 | Published online: 22 Apr 2005
 

Abstract

11β-Hydroxysteroid dehydrogenase-1 (11βHSD1) is a therapeutic target for Type 2 diabetes that has stimulated the interest of many pharmaceutical companies. Mounting evidence obtained from both preclinical and clinical studies support the contention that inhibiting 11βHSD1 will have a therapeutic benefit by lowering glucose output and increasing insulin sensitivity. In just over two years, 21 applications containing 11βHSD1 inhibitors have been published. In this review, the target rationale and patent applications from Merck, Novo Nordisk, AstraZeneca, Sterix, Biovitrum, Janssen and Novartis will be discussed.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.